Tilray | TRLY - Cost Of Sales

Stock Price
10.37
Daily Change
0.74 7.68%
Monthly
-16.71%
Yearly
620.14%
Q1 Forecast
9.94

Tilray reported $164.37M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Alaunos Therapeutics USD 0 18K Sep/2024
Aurora Cannabis CAD 58.08M 11.99M Sep/2025
Avita Medical AUD 3.47M 1.19M Jun/2025
Canopy Growth CAD 44.78M 9.32M Sep/2025
Cronos Group USD 18.36M 1.28M Sep/2025
Divis Laboratories Ltd INR 11.86B 1.18B Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
IQVIA Holdings USD 3.24B 518M Dec/2025
Knight Therapeutics CAD 47.25M 990K Sep/2024
Moderna USD 207M 88M Sep/2025
Organigram Holdings CAD 77.46M 14.63M Sep/2025
Organon & Co USD 745M 25M Sep/2025
Revvity USD 324.34M 3.38M Sep/2025
Tilray USD 164.37M 8.41M Sep/2025
Viatris USD 2.39B 139.2M Sep/2025
Xeris Pharmaceuticals USD 13.71M 1.81M Sep/2025